Related Experiment Video

Updated: Jul 12, 2026

Visualizing Field Data Collection Procedures of Exposure and Biomarker Assessments for the Household Air Pollution Intervention Network Trial in India
09:33

Visualizing Field Data Collection Procedures of Exposure and Biomarker Assessments for the Household Air Pollution Intervention Network Trial in India

Published on: December 23, 2022

Monitoring the randomized trials of the Women's Health Initiative: the experience of the Data and Safety Monitoring

Janet Wittes1, Elizabeth Barrett-Connor, Eugene Braunwald

  • 1Statistics Collaborative, Washington DC, USA. janet@statcollab.com

Clinical Trials (London, England)
|August 24, 2007
PubMed

Insights

Data Safety Monitoring Committees (DSMBs) faced dilemmas with unexpected adverse effects in the Women's Health Initiative trials. This paper details their deliberations and offers recommendations for future committees.

Area of Science:

  • Clinical Trials
  • Pharmacovigilance
  • Cardiovascular Health

Background:

  • Large-scale randomized trials require robust oversight.
  • Emerging data can present unexpected safety concerns.
  • The Women's Health Initiative (WHI) investigated post-menopausal hormone therapy.

Purpose of the Study:

  • To describe the challenges faced by a Data Safety Monitoring Committee (DSMB).
  • To detail the decision-making process regarding unanticipated adverse cardiovascular effects.
  • To provide recommendations for DSMBs managing long-term trials.

Main Methods:

  • Review of the DSMB's deliberations during the WHI trials.
  • Analysis of the considerations made in response to emerging cardiovascular data.
  • Case study approach focusing on ethical and scientific dilemmas.

Main Results:

  • The WHI DSMB encountered significant challenges due to early indications of adverse cardiovascular events.
  • Extended deliberation was required to formulate appropriate recommendations.
  • The committee navigated complex ethical and scientific considerations.

Conclusions:

  • DSMBs managing large trials must be prepared for unforeseen safety signals.
  • Careful deliberation and adaptive strategies are crucial for effective oversight.
  • Lessons learned from the WHI DSMB can inform best practices for other committees.

Related Concept Videos

Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Randomized Experiments01:13

Randomized Experiments

The randomization process involves assigning study participants randomly to experimental or control groups based on their probability of being equally assigned. Randomization is meant to eliminate selection bias and balance known and unknown confounding factors so that the control group is similar to the treatment group as much as possible. A computer program and a random number generator can be used to assign participants to groups in a way that minimizes bias.
Simple randomization
Simple...
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...